SG Americas Securities
ORMP icon

SG Americas Securities’s Oramed Pharmaceuticals ORMP Stock Holding History

SG Americas Securities’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,446
Closed -$50K – 3414
2025
Q1 		$50K Buy
+23,446
New +$54.1K ﹤0.01% 3247
2023
Q1 		– Sell
-10,370
Closed -$125K – 3475
2022
Q4 		$125K Hold
10,370
– – ﹤0.01% 2566
2022
Q3 		$67K Sell
10,370
-36,162
-78% -$293K ﹤0.01% 2944
2022
Q2 		$213K Buy
+46,532
New +$249K ﹤0.01% 2629
2022
Q1 		– Sell
-8,631
Closed -$123K – 3314
2021
Q4 		$123K Sell
8,631
-4,910
-36% -$103K ﹤0.01% 2947
2021
Q3 		$298K Buy
+13,541
New +$231K ﹤0.01% 2950

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

SG Americas Securities's ORMP Position: Q2 2025 in Review

SG Americas Securities sold out of Oramed Pharmaceuticals (ORMP) in Q2 2025, closing a stake of 23,446 shares — an estimated $50K sold.

SG Americas Securities first reported a position in ORMP in Q3 2021 and held it in 6 quarters. The position peaked at $298K in Q3 2021. 47 funds tracked by Wall St. Rank hold ORMP as of Q2 2025.

  • SG Americas Securities reported no remaining Oramed Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 23,446 Oramed Pharmaceuticals shares in Q2 2025, an estimated $50K.
  • SG Americas Securities first reported a position in Oramed Pharmaceuticals in Q3 2021 and held it in 6 quarters.
  • SG Americas Securities's Oramed Pharmaceuticals position peaked at $298K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.